UZEDY® Sales Milestones in 2024
In a remarkable achievement, Medincell's UZEDY® has reached $117 million in total sales for the fiscal year of 2024, marking the first full year of its commercialization. This includes an impressive $43 million generated during the fourth quarter alone.
Comparative Sales Analysis
The recent figures represent a 17% increase from the previous Teva Pharmaceuticals' outlook, which projected sales of $100 million for 2024. The upward trajectory indicates robust demand for UZEDY® as both patients and healthcare providers embrace this innovative treatment.
Quarterly Breakdown of Sales
Sales for each quarter have shown strong performance:
- Q1: $40 million
- Q2: $35 million
- Q3: $43 million
This steady growth showcases the product's increasing acceptance within the market.
Future Projections from Teva Pharmaceuticals
Looking ahead, the initial sales outlook for 2025 from Teva is promising, with projections estimating sales to reach as high as $160 million. This projection is significantly greater than the initial forecast for 2024, which was set at $80 million.
Royalties and Milestone Payments
Medincell is positioned to benefit from this growth through mid- to high-single digit royalties on all sales. Additionally, the company is eligible for up to $105 million in commercial milestone payments, further enhancing its revenue potential as UZEDY® continues to perform well.
Olanzapine Long-Acting Injectable: Next Steps
Medincell is also preparing for the filing and launch of its Olanzapine Long-Acting Injectable, known as TEV-749 / mdc-TJK. The company anticipates the last patient visit of its Phase 3 pivotal trial to occur soon, with long-term safety data expected to be released in the second quarter of 2025.
Regulatory Steps Ahead
The New Drug Application (NDA) submission is anticipated in the second half of 2025, a significant step towards bringing this treatment to the market, potentially expanding Medincell's therapeutic offerings.
About Medincell: A Leader in Biopharmaceuticals
Medincell is an innovative biopharmaceutical company focused on developing long-acting injectable treatments. Their mission includes improving medication adherence, enhancing treatment effectiveness, and reducing environmental impact. Medincell's proprietary BEPO technology allows for the controlled delivery of active ingredients, ensuring that patients receive therapeutic levels over extended periods from just a small injection.
Global Reach and Local Presence
With its headquarters in Montpellier, the company has established a diverse workforce of over 140 employees from more than 25 different nationalities, representing a significant global perspective in its research and development efforts.
Frequently Asked Questions
What is UZEDY® and its significance?
UZEDY® is a long-acting injectable treatment for schizophrenia approved by the FDA, and its success reflects Medincell's innovative approach in the biopharmaceutical sector.
What are the sales expectations for 2024?
Sales for UZEDY® are projected to reach $117 million for 2024, with strong quarterly performance demonstrating high patient acceptance.
What is the outlook for 2025 sales?
Teva's initial outlook for 2025 anticipates UZEDY® sales to grow to around $160 million, indicating continued market expansion.
When can we expect the next regulatory submission for Olanzapine?
The NDA submission for Olanzapine Long-Acting Injectable is expected in the second half of 2025 following successful clinical trials.
How does Medincell plan to use the projected royalties?
Medincell aims to utilize the projected royalties for further research, enhancing their product portfolio, and sustaining their growth in the biopharmaceutical market.
